89Zr-3, 2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin-targeted 227Th-conjugate therapy in mice
The mesothelin (MSLN)-targeted 227Th conjugate is a novel α-therapy developed to treat
MSLN-overexpressing cancers. We radiolabeled the same antibody–chelator conjugate with …
MSLN-overexpressing cancers. We radiolabeled the same antibody–chelator conjugate with …
Tumor and organ uptake of 64Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies
JH Lee, H Kim, Z Yao, SJ Lee, LP Szajek… - Nuclear medicine and …, 2015 - Elsevier
Objectives To investigate the effect of the injection dose of MORAb-009 (amatuximab, an
anti-mesothelin monoclonal antibody), the tumor size and the level of shed mesothelin on …
anti-mesothelin monoclonal antibody), the tumor size and the level of shed mesothelin on …
Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein
N Sato, R Hassan, DB Axworthy, KJ Wong… - Journal of Nuclear …, 2005 - Soc Nuclear Med
Mesothelin is a glycoprotein that is overexpressed in several human tumors, including
mesotheliomas and ovarian cancers, and has been identified as a potential target for …
mesotheliomas and ovarian cancers, and has been identified as a potential target for …
Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody
IS Shin, SM Lee, HS Kim, Z Yao, C Regino… - Nuclear medicine and …, 2011 - Elsevier
INTRODUCTION: Radiolabeling of a monoclonal antibody (mAb) with a metallic
radionuclide requires the conjugation of a bifunctional chelator to the mAb. The conjugation …
radionuclide requires the conjugation of a bifunctional chelator to the mAb. The conjugation …
Evaluation of 111In labeled antibodies for SPECT imaging of mesothelin expressing tumors
R Misri, K Saatchi, SSW Ng, U Kumar… - Nuclear medicine and …, 2011 - Elsevier
INTRODUCTION: Mesothelin is expressed in many cancers, especially in mesothelioma and
lung, pancreatic and ovarian cancers. In the present study, we evaluate 111In labeled …
lung, pancreatic and ovarian cancers. In the present study, we evaluate 111In labeled …
Construction and Preclinical Evaluation of 211At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs
X Wang, W Ma, W Liu, H Ma, Y Yang… - Journal of Radiation …, 2020 - academic.oup.com
Targeted alpha therapy (TAT) is a promising tumor therapy that can specifically transport α
particle to the vicinity of tumor cells while the normal cells are only slightly irradiated …
particle to the vicinity of tumor cells while the normal cells are only slightly irradiated …
Preclinical evaluation of mesothelin-specific ligands for SPECT imaging of triple-negative breast cancer
C Montemagno, S Bacot, M Ahmadi… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Mesothelin is a cell-surface glycoprotein restricted to mesothelial cells overexpressed in
several types of cancer, including triple-negative breast cancer not responding to …
several types of cancer, including triple-negative breast cancer not responding to …
Construction and Preclinical Evaluation of a 124/131I-Labeled Radiotracer for the Detection of Mesothelin-Overexpressing Cancer
X Wang, F Wang, J Han, Z Yang, H Zhu… - Molecular …, 2020 - ACS Publications
Mesothelin is a molecular biomarker of many types of solid cancers, which may represent a
highly promising new target in the development of cancer-targeted diagnostic agents. A …
highly promising new target in the development of cancer-targeted diagnostic agents. A …
ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment
LE Lamberts… - Clinical Cancer …, 2016 - AACR
Purpose: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers,
making it a potential drug target. We performed an 89Zr-PET imaging study with …
making it a potential drug target. We performed an 89Zr-PET imaging study with …
[HTML][HTML] New insight and future perspective of mesothelin-targeted agents in nuclear medicine
M Conte, V Frantellizzi, A Matto… - Clinical and Translational …, 2020 - Springer
Purpose The aim of this review is to summarize the main applications of mesothelin-
targeting agents in the diagnosis of different types of cancers with a brief mention of nuclear …
targeting agents in the diagnosis of different types of cancers with a brief mention of nuclear …